Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Using machine learning to forecast peak health care service demand in real-time during the 2022-23 winter season: A pilot in England, UK.
PLoS One
January 2025
Real-time Syndromic Surveillance Team, Field Services, Health Protection Operations, UK Health Security Agency, Birmingham, United Kingdom.
During winter months, there is increased pressure on health care systems in temperature climates due to seasonal increases in respiratory illnesses. Providing real-time short-term forecasts of the demand for health care services helps managers plan their services. During the Winter of 2022-23 we piloted a new forecasting pipeline, using existing surveillance indicators which are sensitive to increases in respiratory syncytial virus (RSV).
View Article and Find Full Text PDFDonor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study.
Front Transplant
December 2024
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of CHROMETA, KU Leuven, Leuven, Belgium.
Long-term survival after lung transplantation is limited due to chronic lung allograft dysfunction (CLAD), which encompasses two main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for (sub)clinical allograft injury and could be a tool for monitoring of lung allograft health across the (pre)clinical spectrum of CLAD. In this proof-of-concept study, we therefore assessed post-transplant plasma dd-cfDNA levels in 20 CLAD patients (11 BOS and 9 RAS) at three consecutive time points free from concurrent infection or acute rejection, during stable condition, preclinical CLAD, and established CLAD ( = 3 × 20 samples).
View Article and Find Full Text PDFHigh-flow weaning strategies for infants with bronchiolitis: protocol for a pilot randomised controlled trial in the UK.
BMJ Open
November 2024
Department of Acute Child Health, Children's Hospital for Wales, Cardiff, UK.
Article Synopsis
- The study aims to find the best weaning strategy for infants under 12 months with bronchiolitis who are on high-flow nasal cannula (HFNC) therapy, potentially reducing their hospital stay.
- It will compare two weaning methods: one that stops HFNC at a fixed oxygen level and another that transitions to low-flow oxygen after HFNC.
- The trial is being conducted in Wales, involves 20 participants over 24 months, and has ethical approval for its processes and outcomes, which will be shared in a medical journal.
Reduced Serum Brain-Derived Neurotrophic Factor in Infants Affected by Severe Bronchiolitis.
Curr Neuropharmacol
October 2024
Department of Experimental Medicine, Medical Faculty, Sapienza University of Rome, Italy.
Article Synopsis
- Bronchiolitis is a common viral infection in infants that can lead to serious complications, but there are currently no definitive lab tests to gauge severity, aside from demographic factors.
- This study investigated the levels of Brain-Derived Neurotrophic Factor (BDNF) in the serum of infants with bronchiolitis at discharge, finding that those with severe cases had significantly lower BDNF levels.
- The research suggests that low serum BDNF may indicate either increased use by lung cells or decreased production by those cells, highlighting the need for further investigation into this biomarker's role in disease severity.
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical Trial of Inhaled Liposomal Cyclosporine Plus Standard-of-Care Versus Standard-of-Care Alone for Bronchiolitis Obliterans Syndrome After Lung Transplantation.
Ann Transplant
May 2024
Department of Epidemiology, University of Maryland, Baltimore, MD, USA.
BACKGROUND The association between forced expiratory volume in 1 second (FEV1) trajectory and mortality in bronchiolitis obliterans syndrome (BOS) is not well defined. Using long-term data from a prior clinical trial of inhaled liposomal cyclosporine A (L-CsA-I) for lung transplant patients with BOS, this study examined the association between longitudinal FEV₁ change and mortality. MATERIAL AND METHODS We analyzed long-term data from a clinical trial which randomized 21 patients with BOS (³20% decrease in FEV1 from personal maximum) to receive L-CsA-I plus standard-of-care (n=11) or standard-of-care (SOC) alone (n=10) for 24 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!